Search for: [Abstract = "Non ST\-segment elevation acute coronary syndromes \(NSTE ACS\) are the major cause of hospitalization of patients with coronary artery disease \(CAD\). Despite improvement of treatment the short\-term prognosis and long\-term outcome of those patients remain poor. The administration of glycoprotein GP IIb\/IIIa blockers has shown beneficial in recent clinical trials both in conservatively treated patients and after percutaneous coronary interventions \(PCI\). Another option for use of GP IIb\/IIIa blockers with unfractionated heparin are direct thrombin inhibitiors with widely used bivalirudin. The aim of this trial was to compare the efficacy and safety of different anti\-thrombotic regimens in treatment of troponin\-positive NSTE ACS. One hundred patients enrolled in the trial were randomized to two treatment arms\: integrillin \(GP IIb\/IIIa blocker\) with unfractionated heparin or bivalirudin. We found statistically significant difference in the size of the infarct evaluated with enzymatic curves in favour of GP IIb\/IIIa inhibitor \+ unfractionated heparin group. There were no differences between two groups in coronary flow after PCI in TIMI scale in infarct\-related artery and the incidence of bleeding complications. The combined end\-point of death, stroke, repeated myocardial infarction and bleeding complications occurred with no significant difference between the group during in\-hospital, one month and six months follow\-up period."]

Number of results: 0